menu
    • menu
    [{"orgOrder":0,"company":"Noramco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone Methobromide","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Noramco","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Noramco \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Noramco \/ Inapplicable"},{"orgOrder":0,"company":"Purisys LLC","sponsor":"CNBX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"RCC-33","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Purisys LLC","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purisys LLC \/ Purisys LLC","highestDevelopmentStatusID":"4","companyTruncated":"Purisys LLC \/ Purisys LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Noramco

    Menu

    Noramco

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Noramco

                            U.S.A
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

                            Lead Product(s) : Naltrexone Methobromide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Met...

                            Details : Relistor (methylnaltrexone bromide) is an opioid antagonist, its subcutaneous formulation is being investigated in patients with resectable head and neck squamous cell carcinoma.

                            Product Name : Relistor

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Naltrexone Methobromide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Noramco

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Purisys LLC

                            U.S.A
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCC-33

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : CNBX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials

                            Details : Under the agreement, Purisys will support an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA r...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 11, 2021

                            Lead Product(s) : RCC-33

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : CNBX Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Noramco

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth